• No results found

Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open label long term extension studies

N/A
N/A
Protected

Academic year: 2020

Share "Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open label long term extension studies"

Copied!
13
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

Table 1 Baseline demographics and disease characteristics of patients enrolled in the LTE studies
Figure 1 Patient disposition. *Patients who switched multiple times were not included in this analysis; **for patients switching treatment regimens, discontinuations from study within 30 days of treatment switch are reported; ***‘other reasons’ included pa
Figure 2 Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI. Error bars show SE; reductions in patient numbers over time reflect that some patients have not reached time point. BID, twice daily; CDAI, Clinical Disease Activity Index; DAS28-4(ESR), Disease Activity Score in 28 joints, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index.
Figure 3 Proportions of patients achieving (A) DAS28-4(ESR) ≤3.2, (B) CDAI ≤10 and (C) HAQ-DI ≥MCID. Error bars show SE; reductions in patient numbers over time reflect that some patients have not reached time point
+4

References

Related documents

Combination therapy of cyclosporin with methotrexate and gold in rheumatoid arthritis (2 pilot studies).. Tugwell P, Pincus T, Yocum DE, et al Combination therapy with cyclosporine

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase

Efficacy and safety of abatacept in Korean patients with active rheumatoid arthritis and in- adequate response to methotrexate: A phase III, multi- centre,

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in

To compare the efficacy and safety of ABT-494, a novel selective JAK-1 inhibitor, with placebo in patients with moderate-to-severe rheumatoid arthritis (RA) and an inadequate

Damage in Rheumatoid Arthritis Patients With Inadequate Responses to Methotrexate Results From the Double-Blind Treatment Phase of a Randomized Placebo-Controlled

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with

RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage 1) evaluated the efficacy and safety of two doses of certolizumab with methotrexate, or placebo with metho- trexate